Gastrointestinal stromal tumours (GISTs) are rare mesenchymal neoplasms of the gastrointestinal tract and mesentery. They are usually found in the stomach or small intestine but can occur anywhere along the GIT and rarely have extra GI involvement. They are associated with high rates of malignant transformation. Most GISTs present asymptomatically but also present with bleeding, abdominal pain, and rarely gastric outlet obstruction. There have been many risk stratification classifications systems which are calculated based on tumour size, mitotic rate, location, and perforation. They are best identified by computed tomography (CT) scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. The approaches to treating GISTs are to resect primary low-risk tumours, high-risk tumours and further treated with imatinib therapy and unresectable tumours treated with neoadjuvant imatinib 400 mg daily followed by surgical resection and regular follow up by abdominal CT scan.